FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2950073637> ?p ?o ?g. }

• W2950073637 endingPage "56" @default.
• W2950073637 startingPage "56" @default.
• W2950073637 abstract "Background: Antibody-based immunotherapy represents a promising strategy to target chemo-resistant leukemic cells. However, classical antibody-based approaches are restricted to cell surface antigens, even though targeting of intracellular antigens would allow further access to a large number of tumor-specific target structures. Aims: In this study we evaluated a 2+1 T Cell Bispecific (TCB) antibody based on T cell receptor (TCR)-like antibodies for immunotherapy of acute myeloid leukemia (AML). The TCB targets the intracellular tumor antigen Wilms Tumor 1 (WT1) by bivalent recognition of the peptide RMFPNAPYL in the context of human leukocyte antigen allele A∗02:01 (HLA-A2). Complementary binding to CD3ε recruits T cells irrespective of their TCR-specificity. Methods: WT1 expression levels in cancer cell lines and primary AML patient samples at different time points during course of the disease were determined by quantitative real-time PCR, western blot and immunohistochemical staining. WT1-TCB-mediated cytotoxicity was analyzed by co-cultivation of WT1-expressing HLA-A2+ cancer cell lines with T cells from healthy donors. Specific lysis was assessed by flow cytometry. TCR downstream signaling was measured by co-cultivation of primary AML cells with NFAT Luciferase Reporter Jurkat cells. WT1-TCB-mediated cytotoxicity against primary AML cells was evaluated in our pre-established feeder layer-based ex vivo long-term culture system. For in vivo testing, NSG mice (NOD.Cg-Prkdcscid-Il2rgtm1Wjl/SzJ) were humanized with human HLA-A2+ CD34+ cord blood cells. After successful engraftment and development of human T cells, WT1-expressing HLA-A2+ SKM-1 tumor cells were subcutaneously inoculated followed by weekly administration of the WT1-TCB. Results: In accordance with previous reports, we observed WT1 expression in 79% (n = 38) of cancer cell lines and in 92% (n = 65) of AML patient samples at the time of initial diagnosis. Moreover, WT1 expression levels correlated with the percentage of AML blasts: no significant WT1 expression was observed at time of CR (n = 26), whereas WT1 was expressed again at time of relapse (n = 21). WT1-TCBs elicited antibody-mediated T cell cytotoxicity against peptide-pulsed T2 cells and AML cell lines in a WT1 and HLA-restricted manner. Equally, TCR downstream signaling was observed in a WT1-restrictive manner by co-cultivation of primary AML cells with NFAT Luciferase Reporter Jurkat cells. WT1-TCBs further mediated specific lysis of primary AML cells upon addition of allogenic T cells from healthy donors (mean specific lysis: 67 ± 6% after 13–14 days; ± SEM; n = 18). Correspondingly, up-regulation of T cell activation and surrogate exhaustion markers was observed (MFI fold change CD69: 9.3 ± 1.5, PD-1: 5.1 ± 0.7, TIM-3: 4.7 ± 0.6; ± SEM; n = 22). WT1-TCBs also mediated killing of primary AML cells in an autologous setting (mean specific lysis: 38 ± 13% after 13–14 days; ± SEM; n = 5). In comparison with WT1RMF-specific T cells, only bivalent binding by WT1-TCB induced efficient lysis of primary AML cells. Furthermore, WT1-TCB-treated humanized mice bearing SKM-1 tumors showed a dose dependent and significant reduction in tumor growth resulting in tumor control. Summary/Conclusion: TCR-like TCBs targeting of intracellular tumor antigens are a promising tool for cancer immunotherapy. Notably, the 2+1 TCB molecular format for bivalent binding facilitates potent in vitro, ex vivo and in vivo killing of AML cell lines and primary AML samples which present low numbers of the RMF peptide-MHC complex on the cell surface validating WT1-TCB as a promising therapeutic agent for the treatment of AML." @default.
• W2950073637 created "2019-06-27" @default.
• W2950073637 creator A5003069482 @default.
• W2950073637 creator A5011768650 @default.
• W2950073637 creator A5012020159 @default.
• W2950073637 creator A5022787378 @default.
• W2950073637 creator A5026494963 @default.
• W2950073637 creator A5029696518 @default.
• W2950073637 creator A5040318787 @default.
• W2950073637 creator A5054194986 @default.
• W2950073637 creator A5067162282 @default.
• W2950073637 creator A5067282607 @default.
• W2950073637 creator A5070006234 @default.
• W2950073637 creator A5077524499 @default.
• W2950073637 creator A5084056228 @default.
• W2950073637 creator A5086659894 @default.
• W2950073637 creator A5086730170 @default.
• W2950073637 creator A5087757550 @default.
• W2950073637 creator A5088363243 @default.
• W2950073637 creator A5090743158 @default.
• W2950073637 creator A5090750691 @default.
• W2950073637 date "2019-06-01" @default.
• W2950073637 modified "2023-09-26" @default.
• W2950073637 title "PF207 TARGETING WILMS TUMOR 1 WITH A T CELL BISPECIFIC ANTIBODY (WT1-TCB): EX VIVO AND IN VIVO POTENCY BY BIVALENT RECOGNITION OF PEPTIDE-MHC COMPLEXES FROM AN INTRACELLULAR TUMOR ANTIGEN" @default.
• W2950073637 doi "https://doi.org/10.1097/01.hs9.0000559044.46812.aa" @default.
• W2950073637 hasPublicationYear "2019" @default.
• W2950073637 type Work @default.
• W2950073637 sameAs 2950073637 @default.
• W2950073637 citedByCount "0" @default.
• W2950073637 crossrefType "journal-article" @default.
• W2950073637 hasAuthorship W2950073637A5003069482 @default.
• W2950073637 hasAuthorship W2950073637A5011768650 @default.
• W2950073637 hasAuthorship W2950073637A5012020159 @default.
• W2950073637 hasAuthorship W2950073637A5022787378 @default.
• W2950073637 hasAuthorship W2950073637A5026494963 @default.
• W2950073637 hasAuthorship W2950073637A5029696518 @default.
• W2950073637 hasAuthorship W2950073637A5040318787 @default.
• W2950073637 hasAuthorship W2950073637A5054194986 @default.
• W2950073637 hasAuthorship W2950073637A5067162282 @default.
• W2950073637 hasAuthorship W2950073637A5067282607 @default.
• W2950073637 hasAuthorship W2950073637A5070006234 @default.
• W2950073637 hasAuthorship W2950073637A5077524499 @default.
• W2950073637 hasAuthorship W2950073637A5084056228 @default.
• W2950073637 hasAuthorship W2950073637A5086659894 @default.
• W2950073637 hasAuthorship W2950073637A5086730170 @default.
• W2950073637 hasAuthorship W2950073637A5087757550 @default.
• W2950073637 hasAuthorship W2950073637A5088363243 @default.
• W2950073637 hasAuthorship W2950073637A5090743158 @default.
• W2950073637 hasAuthorship W2950073637A5090750691 @default.
• W2950073637 hasBestOaLocation W29500736371 @default.
• W2950073637 hasConcept C147483822 @default.
• W2950073637 hasConcept C150903083 @default.
• W2950073637 hasConcept C153911025 @default.
• W2950073637 hasConcept C154317977 @default.
• W2950073637 hasConcept C159654299 @default.
• W2950073637 hasConcept C19317047 @default.
• W2950073637 hasConcept C202751555 @default.
• W2950073637 hasConcept C203014093 @default.
• W2950073637 hasConcept C207001950 @default.
• W2950073637 hasConcept C26291073 @default.
• W2950073637 hasConcept C2776090121 @default.
• W2950073637 hasConcept C2776662205 @default.
• W2950073637 hasConcept C2777701055 @default.
• W2950073637 hasConcept C2780674031 @default.
• W2950073637 hasConcept C502942594 @default.
• W2950073637 hasConcept C55493867 @default.
• W2950073637 hasConcept C86803240 @default.
• W2950073637 hasConcept C8891405 @default.
• W2950073637 hasConceptScore W2950073637C147483822 @default.
• W2950073637 hasConceptScore W2950073637C150903083 @default.
• W2950073637 hasConceptScore W2950073637C153911025 @default.
• W2950073637 hasConceptScore W2950073637C154317977 @default.
• W2950073637 hasConceptScore W2950073637C159654299 @default.
• W2950073637 hasConceptScore W2950073637C19317047 @default.
• W2950073637 hasConceptScore W2950073637C202751555 @default.
• W2950073637 hasConceptScore W2950073637C203014093 @default.
• W2950073637 hasConceptScore W2950073637C207001950 @default.
• W2950073637 hasConceptScore W2950073637C26291073 @default.
• W2950073637 hasConceptScore W2950073637C2776090121 @default.
• W2950073637 hasConceptScore W2950073637C2776662205 @default.
• W2950073637 hasConceptScore W2950073637C2777701055 @default.
• W2950073637 hasConceptScore W2950073637C2780674031 @default.
• W2950073637 hasConceptScore W2950073637C502942594 @default.
• W2950073637 hasConceptScore W2950073637C55493867 @default.
• W2950073637 hasConceptScore W2950073637C86803240 @default.
• W2950073637 hasConceptScore W2950073637C8891405 @default.
• W2950073637 hasIssue "S1" @default.
• W2950073637 hasLocation W29500736371 @default.
• W2950073637 hasLocation W29500736372 @default.
• W2950073637 hasOpenAccess W2950073637 @default.
• W2950073637 hasPrimaryLocation W29500736371 @default.
• W2950073637 hasRelatedWork W1517459791 @default.
• W2950073637 hasRelatedWork W2069639706 @default.
• W2950073637 hasRelatedWork W2223206920 @default.
• W2950073637 hasRelatedWork W2953447703 @default.
• W2950073637 hasRelatedWork W3013242650 @default.
• W2950073637 hasRelatedWork W3170913590 @default.
• W2950073637 hasRelatedWork W4207055527 @default.

• next